Skip to main content
OpenTrials
Completed

NCT Number: NCT04771624

Assessment of Executive Functions After Covid-19

As it is evident that Covid-19 may have some impacts on cognition, the primary aim of this study is to investigate -if any- deficits of attention, working memory and executive functions after Covid-19.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sağlık Bilimleri Üniversitesi Gazi Yaşargil Training and Research Hospital

Diyarbakır, 21070, Turkey (Türkiye)

About this study

Since Covid-19 (Coronavirus Disease-2019) was declared as a pandemic by the World Health Organization (WHO) on December 31, 2019, it is still widespread and deadly. As an ongoing pandemic, it has led to a panic and then a controlled fear in societies. In many studies, neuropsychological deficits were observed in Covid-19 patients both during the illness and after recovery. A recent study found that impairment in cognitive functions continued after recovery of Covid-19, and it was associated with peripherical inflammatory markers, such as C-Reactive Protein (CRP). CRP, as a peripherical inflammatory marker, has been proven to be inversely related to serum levels of the brain-derived neurotrophic factor (BDNF), an important neurotrophin in the growth and differentiation of neurons. In this study, attention, working memory and executive functions of Covid-19 patients at post-covid period and its relation with the severity of the disease will be investigated.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Covid-19 patients:

  • Diagnosed as Covid-19 by RT-PCR at least 60 days but not more than 90 days ago
  • Asymptomatic at the moment
  • Not having any other general medical, neurological or psychiatric conditions except Covid-19 at the time of acute infection

Healthy subjects:

  • Not having any of Covid-19 symptoms at the testing time point
  • Not having any general medical, neurological or psychiatric condition

Exclusion criteria

Covid-19 patients:

  • Diagnosed as Covid-19 by RT-PCR less than 60 days or more than 90 days ago
  • Having any symptom of acute phase of Covid-19
  • Having any other general medical, neurlogical or psychiatric contidions

Healthy subjects:

  • Having any of Covid-19 symptoms at the testing time point
  • Having any general medical, neurological or psychiatric condition

Treatment and study plan

Primary outcomes

  1. Neuropsychological test scores

    Time frame: Up to 90 days

    Neuropsychological test scores of Covid-19 patients in comparison with healthy control subjects

Secondary outcomes

  1. Severity of the disease

    Time frame: Up to 90 days

    Neuropsychological test score changes according to the disease severity of Covid-19 patients

Sponsors and collaborators

Lead sponsor

Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Other

Registry information

Official study title

May Covid-19 Impair Executive Functions? A Crossectional Study

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Feb 25, 2021
Registry last updated
Nov 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.